BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Maintains $234 Price Target
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Kostas Biliouris has maintained an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a price target of $234.
March 27, 2024 | 2:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BMO Capital maintains an Outperform rating on Alnylam Pharmaceuticals with a $234 price target.
The reaffirmation of an Outperform rating and a high price target by a reputable analyst like Kostas Biliouris from BMO Capital is likely to instill confidence among investors and could lead to a positive short term impact on ALNY's stock price. The specific mention of a $234 price target suggests a strong conviction in the company's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100